Search
Tetrofosmin
go.drugbank.com/drugs/DB11180ApprovedTetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.
Cephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … [A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalIt is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
Telapristone acetate
go.drugbank.com/drugs/DB05253InvestigationalTelapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Azlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Sulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigational[L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.
Difenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitIt is approved by the FDA to treat acute and chronic diarrhea. … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigational[L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]